Regulatory press release

• The new partnership agreement covers the launch and distribution of Enzymatica’s ColdZyme® technology in oral spray form in Germany and Austria

• The partnership combines Enzymatica’s clinically documented medical device with STADA’s comprehensive commercial platform

• The commercial impact is expected to be realized progressively from the 2026/2027 cold and flu season, when STADA will market the product under its own brand names.

Enzymatica AB (publ) and STADA Arzneimittel AG have entered into a partnership agreement regarding the launch and distribution of Enzymatica’s ColdZyme® oral-spray technology in Germany and Austria. The commercial impact is expected to be realized progressively starting from the 2026-2027 colds and flu season.

The new agreement builds on prior experience and collaboration between the two companies in Germany and Austria and combines Enzymatica’s clinically documented medical device with STADA’s comprehensive commercial platform.

Strong commercial platform for long-term growth As part of the amended partnership, STADA will conduct a structured, comprehensive launch of the oral spray in Germany and Austria, where the product will be marketed under STADA’s own brand names. The initiative will be integrated into STADA’s established commercial platform within the group’s Consumer Healthcare segment and will include targeted activities across both pharmacies and digital channels, with a clear focus on the product’s clinical evidence and its unique, differentiated positioning in the category.

As a top five player in Consumer Healthcare in Europe, STADA holds a leading position in Germany, especially in the cough/cold and respiratory market sector. The group intends to use its extensive pharmacy distribution and salesforce, deep consumer insights and 130-year heritage to establish its brands and create long-term value.

“This is a significant breakthrough for Enzymatica. Germany is the largest and most important cold and flu market in Europe. Entering into a partnership with STADA confirms ColdZyme’s competitiveness and commercial relevance. With the right partner in place, we can build long-term and create the conditions for significant volumes over time,” says Sana Alajmovic, CEO of Enzymatica.

“We see the ColdZyme medical-device technology as a strong and clinically differentiated addition to our cold and flu portfolio,” comments Volker Sydow, STADA’s Head and EVP of Global Consumer Healthcare. “With our established pharmacy platform and an integrated marketing strategy, we see attractive opportunities to create long-term value for our retail and commercial partners in the German and Austrian markets.”

Gradual scale-up with clear impact from 2027 Calendar year 2026 will be characterized by preparations, marketing activities, and initial deliveries into Germany and Austria. The more substantial commercial impact is expected to be realized progressively from the 2027 colds and flu season, when the initiative will be fully integrated into STADA’s Consumer Healthcare marketing and campaign structure.

The information in this press release is information that Enzymatica is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on 31 March 2026 at 14:00 CEST.